Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Variability in the Performance of Nuclear Matrix Protein 22 for the Detection of Bladder Cancer

9 Aug 2006

Abstract excerpt

PURPOSE: We assessed variability in the diagnostic performance of NMP22 for detecting recurrence and progression in patients with Ta, T1, and/or CIS transitional cell carcinoma of the bladder in a large international cohort. MATERIALS AND METHODS: NMP22 voided urine levels were measured in 2,871 patients who underwent office cystoscopy for monitoring previous stage Ta, T1 and/or CIS transitional cell carcinoma at...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Bladder and Urothelial Cancer Treatments
Share to Peptidase Inhibition and Analysis
Share to Urinary and Genital Oncology Studies

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 16890655
DOI: 10.1016/j.juro.2006.04.017

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Variability in the Performance of Nuclear Matrix Protein 22 for the Detection of Bladder CancerPMID 16890655Read ↗

Improving diagnostic molecular tests to monitor urothelial carcinoma recurrence.Semantic proximity Read ↗

A urinary assay for mutation and methylation biomarkers in the diagnosis and recurrence prediction of non-muscle invasive bladder cancer patients.Semantic proximity Read ↗

Urinary DNA Methylation Test for Bladder Cancer DiagnosisSemantic proximity Read ↗

Distinct longitudinal patterns of urine tumor DNA in patients undergoing surveillance for bladder cancerSemantic proximity Read ↗

Uromonitor: Clinical Validation and Performance Assessment of a Urinary Biomarker Within the Surveillance of Patients With Nonmuscle-Invasive Bladder Cancer.Semantic proximity Read ↗

An evaluation of urinary microRNA reveals a high sensitivity for bladder cancerSemantic proximity Read ↗

TERT C228T mutation in non-malignant bladder urothelium is associated with intravesical recurrence for patients with non-muscle invasive bladder cancer.Semantic proximity Read ↗

Comparison of 2 new real‐time polymerase chain reaction–based urinary markers in the follow‐up of patients with non–muscle‐invasive bladder cancerSemantic proximity Read ↗

Diagnostic value of fibronectin and mutant p53 in the urine of patients with bladder cancer: impact on clinicopathological features and disease recurrence.Semantic proximity Read ↗

Bladder cancer screening in a high risk asymptomatic population using a point of care urine based protein tumor marker.Semantic proximity Read ↗

Surveillance patterns in non-muscle invasive bladder cancer across risk groups: a real-world analysisSemantic proximity Read ↗

Voided Urine Fluorescence In Situ Hybridization Testing for Upper Tract Urothelial Carcinoma SurveillanceSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.